Healthcare professionals

AfA is here to help you care for and manage patients living with HIV/AIDS. Access our team of clinical HIV experts to get support, ask for advice and discuss complex clinical challenges. Explore our protocols, guidelines, publications and clinical intelligence.

doctors

CPD online training

Gain HIV management skills.

Online modular training for doctors and other healthcare professionals in HIV medicine offers a practical solution to gain HIV management skills. It is particularly suitable for those working outside of the major centres.

You can complete individual modules or the full training programme.

  • The modules cover the basics of HIV management and reflect current best practice, both nationally and internationally.
  • Each module is CPD-accredited with a CPD certificate issued online following successful answering of several multiple-choice questions.
  • All the modules will be updated annually.
  • There will be a dedicated annual HIV update module based on new guidelines and advances in HIV management.

Registration on the course is free of charge and is open to all doctors as well as other interested healthcare professionals.

Please go here to register, using your professional council registration number, and follow the simple instructions. If you do not have a professional council number your ID number may be used.

The course has been developed by Professor Gary Maartens, who is an acknowledged expert in HIV management and has participated in the development of HIV treatment guidelines both nationally and internationally. He has been involved in teaching and research in HIV medicine for many years and has been a senior consultant on the AfA Clinical Advisory Committee since its inception in 1998.

Publications and Presentations

AfA has spoken at and participated in local and international conferences, had its collaborative research published and been invited to speak at a variety of organisations. Our approach is to share our expertise on the clinical, programmatic and behavioural aspects of managing HIV in different settings freely.

Newsletters

June 2011

  • ART for Prevention
  • Cryptococcal antigen screening in patients with CD4 <= 100

May 2011

  • Efavirenz dose for paediatric patients
  • Raltegravir: what is the place of the new kid on the block?
  • When is the optimal time to start ART in patients with TB? Recent findings
  • African RCT of influenza vaccination in HIV shows benefit and safety

December 2010

  • Pre-exposure prophylaxis
  • CD4 counts and percentages in children
  • ART resistance, genotype resistance testing and archiving
  • Amphotericin B

October 2010

  • Patients with poor adherence to first line ART (2 NRTIs + 1 NNRTI) who have a persistently non-suppressed viral load
  • Antimalarial chemoprophylaxis and treatment
  • Newer protease inhibitors do not cause diabetes

July 2010

  • Single drug switch from Stavudine (or Zidovudine) to Tenofovir
  • Long-term Isoniazid preventive therapy for HIV-infected adults: new evidence
  • Immunisation and HIV in adults
  • Immunisation in HIV-infected children and adolescents – emerging perspectives in 2010

February 2010

  • HIV and pandemic influenza; lessons learnt and what to expect?
  • Differential diagnoses to consider in a patient with suspended TB
  • Using nevirapine-based are in patients with TB
  • Use of Ritonavir(Norvir®) as single protease inhibitor in infants and childern
  • Discontinuation notice: Kaletra® soft gel capsules

October 2009

  • When is the best time to start antiretroviral therapy?
  • Elective caesarean sections and HIV transmission
  • Genotyping testing for antiretroviral resistance
  • Use of Stavudine(D4T) as part of combination therapy
  • Antibiotics to prevent STIs post sexual assault

April 2009

  • Antiretrovirals and the liver
  • Isoniazid (INH) prophylaxis for HIV-infected children
  • Isoniazid preventive therapy for HIV-infected healthcare workers
  • Risk factors for nephrotoxicity in patients on Tenofovir
  • Zidovudine (AZT) dose adjustment for infants
  • Pneumonia in patients with HIV infection

January 2009

  • Abacavir and the risk of myocardial infarction
  • New insights in infant feeding – breast versus formula
  • New Southern African HIV Clinicians Society suidelines for post-exposure prophylaxis
  • Switching antiretrovirals for lipodystrophy

June 2008

  • Antiretroviral therapy and the risk of myocardial infarction
  • Aluvia tablets replace Kaletra
  • Diagnosis of Mycobacterium Avium Complex (MAC) infection
  • TDF (Tenofovir Disporoxil Fumarate) in special situations
  • Antiretroviral resistance testing (genotyping)

November 2007

  • Atazanavir
  • Resistance mutations and Atazanavir
  • Early antiretroviral therapy (ART) in infants
  • Hepatotoxicity when using adjusted dose Kaletra® with Rifampicin
  • Clinical, virological and immunological responses to HAART
  • NNRTI vs boosted PI regimens

July 2007

  • The use of Tenofovir Disoproxil Fumarate (TDF) in HAART regimens
  • Resistance patterns associated with decreased Tenofovir efficacy
  • Emtricitabine (FTC)
  • Tenofovir: side effects and toxicities
  • Hepatitis B
  • The use of Tenofovir in pregnancy and in paediatric patients
  • Monitoring patients on Tenofovir
  • Viread® and Truvada®
  • Tenofovir drug interactions